Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Cash from Operations (2019 - 2025)

Goldenwell Biotech's Cash from Operations history spans 7 years, with the latest figure at 30885.0 for Q3 2025.

  • For Q3 2025, Cash from Operations fell 47.32% year-over-year to 30885.0; the TTM value through Sep 2025 reached 29133.0, up 75.06%, while the annual FY2024 figure was 123077.0, 8.77% down from the prior year.
  • Cash from Operations reached 30885.0 in Q3 2025 per GWLL's latest filing, down from 59380.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 59380.0 in Q2 2025 to a low of 917090.0 in Q4 2022.
  • Average Cash from Operations over 5 years is 86571.16, with a median of 29010.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: tumbled 105675.35% in 2021, then surged 224.35% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 19373.0 in 2021, then plummeted by 4633.86% to 917090.0 in 2022, then soared by 97.92% to 19076.0 in 2023, then plummeted by 32.89% to 25351.0 in 2024, then decreased by 21.83% to 30885.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Cash from Operations are 30885.0 (Q3 2025), 59380.0 (Q2 2025), and 32277.0 (Q1 2025).